Screener
NewAmsterdam Pharma Company NAMS Accounts Payable Current
Accounts Payable Current at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: NewAmsterdam Pharma Company’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333824
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Total assets | 704,452 | 769,284 |
| Liabilities and Shareholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | 5,422 | 8,970 |
| Accrued expenses and other current liabilities | 10,277 | 15,422 |
| Deferred revenue, current | 2,797 | 3,987 |
| Lease liability, current | 26 | 136 |
| Derivative warrant liabilities | 54,452 | 57,272 |
Item 1. Financial Statements.
FAQ
- What is NewAmsterdam Pharma Company's accounts payable current?
- NewAmsterdam Pharma Company (NAMS) reported accounts payable current of $5.42M in Q2 2026.
- How has NewAmsterdam Pharma Company's accounts payable current changed year-over-year?
- NewAmsterdam Pharma Company's accounts payable current decreased by 8.0% year-over-year, from $5.9M to $5.42M.
- What is the long-term trend for NewAmsterdam Pharma Company's accounts payable current?
- Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's accounts payable current has grown at a -8.9% compound annual growth rate (CAGR), from $11.85M to $8.97M.
- What does accounts payable current mean?
- Accounts Payable Current as reported by NewAmsterdam Pharma Company N.V. Ordinary Shares.
Ask your AI about NewAmsterdam Pharma Company's accounts payable current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude